Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3229479 | 0.83 | HTT (0.39) | MAPK14NPSR1ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL3217612 | 0.75 | MAPK14 (0.52) | MAPK14RAF1HPGDALDH1A1MAPT | |
| SCHEMBL10308265 | 0.73 | MAPK14 (0.50) | MAPK14RAF1HPGDALDH1A1KDM4E | |
| SCHEMBL6178084 | 0.72 | TDP1 (0.41) | VCAM1HPGDALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL11226555 | 0.69 | VCAM1 (0.56) | VCAM1NPSR1HPGDALDH1A1HTT | |
| SCHEMBL22493011 | 0.69 | ALDH1A1 (0.54) | VCAM1NPSR1HPGDALDH1A1HTT | |
| SCHEMBL1878446 | 0.68 | TDP1 (0.57) | HPGDKDM4EGAATDP1 | |
| SCHEMBL11512029 | 0.68 | PDGFRB (0.49) | VCAM1NPSR1HPGDALDH1A1HTT | |
| SCHEMBL28723068 | 0.67 | PDGFRB (0.48) | VCAM1NPSR1HPGDALDH1A1HTT | |
| SCHEMBL3550374 | 0.66 | RAF1 (0.47) | MAPK14RAF1VCAM1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| EP-0986382-B1 | RAF KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20050256174-A1 | Raf kinase inhibitors | BAYER HEALTHCARE LLC | 2005-11-17 | — | — | US | disclosed |
| EP-1019040-B1 | ARYL UREAS FOR THE TREATMENT OF INFLAMMATORY OR IMMUNOMODULATORY DISEASES | BAYER AG (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | disclosed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | disclosed |
| US-20010006975-A1 | Raf kinase inhibitors | BAYER CORPORATION AND ONYX PHARMACEUTICALS WEST HAVEN, CT AND RICHMOND, CA, RESPECTIVELY | 2001-07-05 | — | — | US | disclosed |
| US-6187799-B1 | TREATING CANCEROUS CELL GROWTH MEDIATED BY RAF KINASE BY ADMINISTERING SPECIFIED COMPOUNDS, SUCH AS 2-(METHYOXYCARBONYL),3-((4-METHYLPHENYL)UREA),5-ALKYL-THIOPHENE | ONYX PHARMACEUTICALS | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | MAPK1, MAP3K1, MAP3K7 | MAPK14 40/4885RAF1 237/4885VCAM1 2815/4885 |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | MAPK1, MAP3K1, MAP3K7 | MAPK14 40/4885RAF1 237/4885VCAM1 2815/4885 |
| US-20100063088-A1 | Raf Kinase Inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885RAF1 2/4885VCAM1 3882/4885 |
| US-20050256174-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885RAF1 2/4885VCAM1 3882/4885 |
| US-20120178780-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | MAPK14 239/4885RAF1 2/4885VCAM1 3882/4885 |
| US-20010006975-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | MAPK14 239/4885RAF1 2/4885VCAM1 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.